BeiGene, Ltd. (BGNE)
After hours:
| Previous close | 240.40 |
| Open | 240.38 |
| Bid | 239.54 x 100 |
| Ask | 240.92 x 100 |
| Day's range | 237.55 - 243.83 |
| 52-week range | 126.97 - 248.16 |
| Volume | |
| Avg. volume | 311,615 |
| Market cap | 26.636B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
SAN MATEO, Calif., September 26, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recognizes the favorable benefit-risk profile of PD-1 inhibitors, including TEVIMBRA® (tislelizumab-jsgr), for the first-line treatment of patients with locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC) expressing PD-L1 (>1%) and gastric/gastroes
- Business Wire
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
SAN MATEO, Calif., September 26, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Shalini Sharp to its Board of Directors and as a member of the Board’s Audit Committee, effective September 27, 2024.
- Business Wire
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
HERZLIYA, Israel, September 17, 2024--Tevimbra has been approved in Israel
